UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | April 27, 2010 |
Boston Scientific Corporation
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 1-11083 | 04-2695240 |
| _____________________ (State or other jurisdiction | _____________ (Commission | ______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| One Boston Scientific Place, Natick, Massachusetts | 01760-1537 | |
| _________________________________ (Address of principal executive offices) | ___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 508-650-8000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 27, 2010, we announced that the U.S. District Court in Minnesota declined to accept the plea agreement between Guidant and the U.S. Department of Justice (DOJ) related to product advisories issued in 2005, before we acquired Guidant. Instead, the Court invited the parties to consider a modified agreement fashioned to further serve the public interest, including community service, public education and charitable activities, and suggested the DOJ allocate a portion of the settlement funds to Medicare. The Court did not suggest revisions to the remaining terms of the plea agreement.
We plan to work with the DOJ in an effort to develop a modified plea agreement that is acceptable to the Court, the DOJ and the Company.
In November, Guidant agreed to plead to two misdemeanor charges related to the failure to include information in reports to the U.S. Food and Drug Administration, and we agreed to pay $296 million on behalf of Guidant.
A copy of the press release is attached as Exh ibit 99.1 hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Boston Scientific Corporation | ||||
| April 27, 2010 | By: | Lawrence J. Knopf | ||
| Name: Lawrence J. Knopf | ||||
| Title: Senior Vice President and Deputy General Counsel | ||||
Exhibit Index
| Exhibit No. | Description | |
99.1 | Press release issued by Boston Scientific Corporation dated April 27, 2010. |